<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37342346</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Telitacicept for autoimmune nephropathy.</ArticleTitle><Pagination><StartPage>1169084</StartPage><MedlinePgn>1169084</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1169084</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1169084</ELocationID><Abstract><AbstractText>B cells and the humoral immunity are important players in the pathogenesis of autoimmune diseases. BAFF (also known as BLYS) and a proliferation-inducing ligand APRIL are required for the maintenance of the B-cell pool and humoral immunity. BAFF and APRIL can promote B-cell differentiation, maturation, and plasma cell antibody secretion. BAFF/APRIL overexpression has been identified in several autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, IgA nephropathy, etc. Telitacicept, a novel fully human TACI-Fc fusion protein that binds both BAFF and APRIL, was approved in China in March 2021 for the treatment of systemic lupus erythematosus at a recommended dose of 160 mg/w subcutaneously and is in clinical trials for the treatment of multiple indications in other autoimmune diseases. In this review, we explored telitacicept's mechanism of action and clinical data. In addition, the immune features of autoimmune nephropathy were discussed, emphasizing lupus nephritis, IgA nephropathy, and membranous nephropathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Cai, Gao, Liu and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henan Province Research Center for Kidney Disease, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dongwei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henan Province Research Center for Kidney Disease, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhangsuo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henan Province Research Center for Kidney Disease, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722462">telitacicept</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053264">B-Cell Activating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005922" MajorTopicYN="Y">Glomerulonephritis, IGA</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053264" MajorTopicYN="N">B-Cell Activating Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell activating factor BAFF</Keyword><Keyword MajorTopicYN="N">IgA nephropathy</Keyword><Keyword MajorTopicYN="N">a proliferation-inducing ligand APRIL</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">telitacicept</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>11</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37342346</ArticleId><ArticleId IdType="pmc">PMC10277628</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1169084</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang L, Xu X, Zhang M, Hu C, Zhang X, Li C, et al. . Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance. JAMA Intern Med (2023) 183(4):298&#x2013;310. doi:&#xa0;10.1001/jamainternmed.2022.6817</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.6817</ArticleId><ArticleId IdType="pmc">PMC9941971</ArticleId><ArticleId IdType="pubmed">36804760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. . Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 379(9818):815&#x2013;22. doi:&#xa0;10.1016/S0140-6736(12)60033-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60033-6</ArticleId><ArticleId IdType="pubmed">22386035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Wang H, Zhao X, Matsushita K, Coresh J, Zhang L, et al. . Ckd in China: evolving spectrum and public health implications. Am J Kidney Dis (2020) 76(2):258&#x2013;64. doi:&#xa0;10.1053/j.ajkd.2019.05.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.05.032</ArticleId><ArticleId IdType="pubmed">31492486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J-H, Zhu H-X, Zhou M-L, Le W-B, Zeng C-H, Liang S-S, et al. . Changes in the spectrum of kidney diseases: an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China. Kidney Dis (Basel) (2018) 4(1):10&#x2013;9. doi:&#xa0;10.1159/000484717</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484717</ArticleId><ArticleId IdType="pmc">PMC5848489</ArticleId><ArticleId IdType="pubmed">29594138</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdsworth SR, Gan PY, Kitching AR. Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol (2016) 12(4):217&#x2013;31. doi:&#xa0;10.1038/nrneph.2016.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.18</ArticleId><ArticleId IdType="pubmed">26949177</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier E, Jayne D, D&#xf6;rner T. Targeting b cells and plasma cells in glomerular diseases: translational perspectives. J Am Soc Nephrol (2018) 29(3):741&#x2013;58. doi:&#xa0;10.1681/ASN.2017040367</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2017040367</ArticleId><ArticleId IdType="pmc">PMC5827591</ArticleId><ArticleId IdType="pubmed">29326157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. medical immunology. 9th Ed. Beijing: People's Medical Publishing House; (2018) p. 78&#x2013;80.</Citation></Reference><Reference><Citation>Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol (2016) 12(4):232&#x2013;40. doi:&#xa0;10.1038/nrneph.2016.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.20</ArticleId><ArticleId IdType="pubmed">26923204</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The role of baff and April in rheumatoid arthritis. J Cell Physiol (2019) 234(10):17050&#x2013;63. doi:&#xa0;10.1002/jcp.28445</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28445</ArticleId><ArticleId IdType="pubmed">30941763</ArticleId></ArticleIdList></Reference><Reference><Citation>Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. . Baff mediates survival of peripheral immature b lymphocytes. J Exp Med (2000) 192(10):1453&#x2013;66. doi:&#xa0;10.1084/jem.192.10.1453</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.192.10.1453</ArticleId><ArticleId IdType="pmc">PMC2193190</ArticleId><ArticleId IdType="pubmed">11085747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay F, Schneider P, Rennert P, Browning J. Baff and April: a tutorial on b cell survival. Annu Rev Immunol (2003) 21:231&#x2013;64. doi:&#xa0;10.1146/annurev.immunol.21.120601.141152</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.21.120601.141152</ArticleId><ArticleId IdType="pubmed">12427767</ArticleId></ArticleIdList></Reference><Reference><Citation>Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, et al. . A proliferation inducing ligand (April) targeted antibody is a safe and effective treatment of murine iga nephropathy. Kidney Int (2019) 96(1):104&#x2013;16. doi:&#xa0;10.1016/j.kint.2019.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.01.031</ArticleId><ArticleId IdType="pubmed">31027890</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. . April Is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 111(5):2755&#x2013;64. doi:&#xa0;10.1182/blood-2007-09-110858</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-09-110858</ArticleId><ArticleId IdType="pubmed">18180376</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. T Cells and autoimmune kidney disease. Nat Rev Nephrol (2017) 13(6):329&#x2013;43. doi:&#xa0;10.1038/nrneph.2017.34</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.34</ArticleId><ArticleId IdType="pubmed">28287110</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol (2012) 2012:1&#x2013;9. doi:&#xa0;10.1155/2012/604892</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/604892</ArticleId><ArticleId IdType="pmc">PMC3368358</ArticleId><ArticleId IdType="pubmed">22690240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Internal Med (2020) 172(11):ITC81&#x2013;96. doi:&#xa0;10.7326/aitc202006020</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/aitc202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Munoz-Valle JF, et al. . Association of baff, April serum levels, baff-r, taci and bcma expression on peripheral b-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus (2016) 25(6):582&#x2013;92. doi:&#xa0;10.1177/0961203315608254</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315608254</ArticleId><ArticleId IdType="pubmed">26424128</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. . Association of plasma b lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum (2008) 58(8):2453&#x2013;9. doi:&#xa0;10.1002/art.23678</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23678</ArticleId><ArticleId IdType="pubmed">18668552</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. . Raised serum April levels in patients with systemic lupus erythematosus. Ann Rheum Dis (2005) 64(7):1065&#x2013;7. doi:&#xa0;10.1136/ard.2004.022491</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.022491</ArticleId><ArticleId IdType="pmc">PMC1755547</ArticleId><ArticleId IdType="pubmed">15576416</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus (2006) 15(9):570&#x2013;6. doi:&#xa0;10.1177/0961203306071871</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306071871</ArticleId><ArticleId IdType="pubmed">17080911</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancro MP, D'Cruz DP, Khamashta MA. The role of b lymphocyte stimulator (Blys) in systemic lupus erythematosus. J Clin Invest (2009) 119(5):1066&#x2013;73. doi:&#xa0;10.1172/JCI38010</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI38010</ArticleId><ArticleId IdType="pmc">PMC2673851</ArticleId><ArticleId IdType="pubmed">19411764</ArticleId></ArticleIdList></Reference><Reference><Citation>Pers J-O, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. . Baff overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci (2005) 1050:34&#x2013;9. doi:&#xa0;10.1196/annals.1313.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1313.004</ArticleId><ArticleId IdType="pubmed">16014518</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Metyas S, Tan S-M, Cheema GS, Oamar B, Xu D, et al. . B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum (2003) 48(12):3475&#x2013;86. doi:&#xa0;10.1002/art.11354</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11354</ArticleId><ArticleId IdType="pubmed">14673998</ArticleId></ArticleIdList></Reference><Reference><Citation>Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, et al. . Intrarenal production of b-cell survival factors in human lupus nephritis. Modern Pathol (2010) 24(1):98&#x2013;107. doi:&#xa0;10.1038/modpathol.2010.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2010.184</ArticleId><ArticleId IdType="pubmed">20890272</ArticleId></ArticleIdList></Reference><Reference><Citation>Huard B, Tran NL, Benkhoucha M, Manzin-Lorenzi C, Santiago-Raber ML. Selective April blockade delays systemic lupus erythematosus in mouse. PloS One (2012) 7(2):e31837. doi:&#xa0;10.1371/journal.pone.0031837</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031837</ArticleId><ArticleId IdType="pmc">PMC3280206</ArticleId><ArticleId IdType="pubmed">22355399</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran NL, Schneider P, Santiago-Raber ML. Taci-dependent April signaling maintains autoreactive b cells in a mouse model of systemic lupus erythematosus. Eur J Immunol (2017) 47(4):713&#x2013;23. doi:&#xa0;10.1002/eji.201646630</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646630</ArticleId><ArticleId IdType="pubmed">28267197</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (2011) 377(9767):721&#x2013;31. doi:&#xa0;10.1016/S0140-6736(10)61354-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov&#xe1; D, et al. . A phase iii, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits b lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 63(12):3918&#x2013;30. doi:&#xa0;10.1002/art.30613</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med (2020) 383(12):1117&#x2013;28. doi:&#xa0;10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Xiao Y, Tang Y, Zheng X, Anwar M, Qin W. Clinical and pathological features of immunoglobulin a nephropathy patients with nephrotic syndrome. Clin Exp Med (2019) 19(4):479&#x2013;86. doi:&#xa0;10.1007/s10238-019-00580-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-019-00580-9</ArticleId><ArticleId IdType="pubmed">31542837</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Zhao M. Nephrology. 3rd Ed. Beijing: People's Medical Publishing House; (2021) p. 15&#x2013;6.</Citation></Reference><Reference><Citation>Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, et al. . Toll-like receptor 9 affects severity of iga nephropathy. J Am Soc Nephrol (2008) 19(12):2384&#x2013;95. doi:&#xa0;10.1681/ASN.2007121311</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2007121311</ArticleId><ArticleId IdType="pmc">PMC2588104</ArticleId><ArticleId IdType="pubmed">18776126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, et al. . Tonsillar Tlr9 expression and efficacy of tonsillectomy with steroid pulse therapy in iga nephropathy patients. Nephrol Dial Transplant (2012) 27(3):1090&#x2013;7. doi:&#xa0;10.1093/ndt/gfr403</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfr403</ArticleId><ArticleId IdType="pubmed">21778277</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DD, Chiu S, Gao Y, Summers-deLuca LE, Gommerman JL. Baff induces a hyper-iga syndrome in the intestinal lamina propria concomitant with iga deposition in the kidney independent of light. Cell Immunol (2006) 241(2):85&#x2013;94. doi:&#xa0;10.1016/j.cellimm.2006.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2006.08.002</ArticleId><ArticleId IdType="pubmed">16987502</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Peng X, Liu Y, Liu H, Liu F, He L, et al. . Tlr9 and baff: their expression in patients with iga nephropathy. Mol Med Rep (2014) 10(3):1469&#x2013;74. doi:&#xa0;10.3892/mmr.2014.2359</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2359</ArticleId><ArticleId IdType="pubmed">24993857</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin G, Shi W, Xu L-X, Su Y, Yan L-J, Li K-S. Serum baff is elevated in patients with iga nephropathy and associated with clinical and histopathological features. J Nephrol (2013) 26(4):683&#x2013;90. doi:&#xa0;10.5301/jn.5000218</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/jn.5000218</ArticleId><ArticleId IdType="pubmed">23042433</ArticleId></ArticleIdList></Reference><Reference><Citation>Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, et al. . Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center b cells in iga nephropathy. J Am Soc Nephrol (2017) 28(4):1227&#x2013;38. doi:&#xa0;10.1681/ASN.2016050496</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016050496</ArticleId><ArticleId IdType="pmc">PMC5373453</ArticleId><ArticleId IdType="pubmed">27920152</ArticleId></ArticleIdList></Reference><Reference><Citation>Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, et al. . Tlr9 activation induces aberrant iga glycosylation Via April- and il-6-Mediated pathways in iga nephropathy. Kidney Int (2020) 97(2):340&#x2013;9. doi:&#xa0;10.1016/j.kint.2019.08.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.08.022</ArticleId><ArticleId IdType="pmc">PMC7372907</ArticleId><ArticleId IdType="pubmed">31748116</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009) 361(1):11&#x2013;21. doi:&#xa0;10.1056/NEJMoa0810457</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810457</ArticleId><ArticleId IdType="pmc">PMC2762083</ArticleId><ArticleId IdType="pubmed">19571279</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. . Membranous nephropathy. Nat Rev Dis Primers (2021) 7(1):69. doi:&#xa0;10.1038/s41572-021-00303-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00303-z</ArticleId><ArticleId IdType="pubmed">34593809</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Li J, He F, Lv Y, Liu W, Wu P, et al. . The diagnosis accuracy of Pla2r-ab in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PloS One (2014) 9(8):e104936. doi:&#xa0;10.1371/journal.pone.0104936</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104936</ArticleId><ArticleId IdType="pmc">PMC4138154</ArticleId><ArticleId IdType="pubmed">25136841</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu C-M, et al. . Baff is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 201(2):195&#x2013;200. doi:&#xa0;10.1084/jem.20041674</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041674</ArticleId><ArticleId IdType="pmc">PMC2212784</ArticleId><ArticleId IdType="pubmed">15642740</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SS, Yang SH, Choi M, Kim H-R, Kim K, Lee S, et al. . The role of tnf superfamily member 13 in the progression of iga nephropathy. J Am Soc Nephrol (2016) 27(11):3430&#x2013;9. doi:&#xa0;10.1681/ASN.2015060677</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2015060677</ArticleId><ArticleId IdType="pmc">PMC5084881</ArticleId><ArticleId IdType="pubmed">27068226</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SS, Yang SH, Jo HA, Oh YJ, Park M, Kim JY, et al. . Baff and April expression as an autoimmune signature of membranous nephropathy. Oncotarget (2018) 9(3):3292&#x2013;302. doi:&#xa0;10.18632/oncotarget.23232</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.23232</ArticleId><ArticleId IdType="pmc">PMC5790464</ArticleId><ArticleId IdType="pubmed">29423047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pell&#xe9; T, Gaspari F, et al. . Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol (2015) 26(10):2545&#x2013;58. doi:&#xa0;10.1681/ASN.2014070640</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2014070640</ArticleId><ArticleId IdType="pmc">PMC4587688</ArticleId><ArticleId IdType="pubmed">25804280</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Kinnman N, Tak PP. Targeting b cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther (2010) 125(3):464&#x2013;75. doi:&#xa0;10.1016/j.pharmthera.2010.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2010.01.001</ArticleId><ArticleId IdType="pubmed">20097226</ArticleId></ArticleIdList></Reference><Reference><Citation>
Remegen Pharmaceuticals Inc . Mechanism of action for telitacicept (2022). Available at: http://www.Remegen.Com/Index.Php?V=Show&amp;Cid=93&amp;Id=147/ (Accessed 31 Oct 2022).</Citation></Reference><Reference><Citation>Chen X, Hou Y, Jiang J, Zhao Q, Zhong W, Wang W, et al. . Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of rct-18 in Chinese patients with rheumatoid arthritis. Clin Pharmacokinet (2014) 53(11):1033&#x2013;44. doi:&#xa0;10.1007/s40262-014-0175-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-014-0175-9</ArticleId><ArticleId IdType="pubmed">25179916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W, et al. . Pharmacokinetics, pharmacodynamics, short term efficacy and safety of rct-18, a novel Blys/April fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol (2016) 82(1):41&#x2013;52. doi:&#xa0;10.1111/bcp.12908</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12908</ArticleId><ArticleId IdType="pmc">PMC4917793</ArticleId><ArticleId IdType="pubmed">26917504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Chen X, Hou Y, Jiang J, Zhong W, Yao X, et al. . Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of rct-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol (2016) 56(8):948&#x2013;59. doi:&#xa0;10.1002/jcph.686</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.686</ArticleId><ArticleId IdType="pubmed">26634642</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Fan X, Su Y, Zhou H, Cao S, Zhu X, et al. . Pharmacokinetic characteristics, safety, and tolerability of telitacicept, an injectable recombinant human b-lymphocyte stimulating factor receptor-antibody fusion protein, in healthy Chinese subjects. Clin Pharmacol Drug Dev (2022) 11(11):1273&#x2013;83. doi:&#xa0;10.1002/cpdd.1136</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.1136</ArticleId><ArticleId IdType="pmc">PMC9796261</ArticleId><ArticleId IdType="pubmed">35844038</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum (2012) 64(4):1215&#x2013;26. doi:&#xa0;10.1002/art.34359</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2022) 81(1):100&#x2013;7. doi:&#xa0;10.1136/annrheumdis-2021-220920</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al. . Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-Four-Week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase iib study. Arthritis Rheumatol (2018) 70(2):266&#x2013;76. doi:&#xa0;10.1002/art.40360</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40360</ArticleId><ArticleId IdType="pmc">PMC6099253</ArticleId><ArticleId IdType="pubmed">29073347</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel b cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther (2009) 9(7):909&#x2013;19. doi:&#xa0;10.1517/14712590903033919</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712590903033919</ArticleId><ArticleId IdType="pubmed">19522556</ArticleId></ArticleIdList></Reference><Reference><Citation>
Remegen Pharmaceuticals Inc . Telitacicept has been reconfirmed for myasthenia gravis (2022). Available at: http://www.Remegen.Cn/Index.Php?V=Show&amp;Cid=39&amp;Id=938/ (Accessed 17 Nov 2022).</Citation></Reference><Reference><Citation>Wu D, Li J, Xu D, Wang W, Li L, Fang J, et al. . A human recombinant fusion protein targeting b lymphocyte stimulator (Blys) and a proliferation-inducing ligand (April), telitacicept (Rc18), in systemic lupus erythematosus (Sle): results of a phase 2b study [Abstract]. Arthritis Rheumatol (2019) 71(Suppl 10).</Citation></Reference><Reference><Citation>Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, et al. . Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus (2022) 31(8):998&#x2013;1006. doi:&#xa0;10.1177/09612033221097812</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221097812</ArticleId><ArticleId IdType="pubmed">35499216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Li J, Xu D, Wang L, Fang J, Ross D, et al. . Telitacicept, a human recombinant fusion protein targeting b lymphocyte stimulator (Blys) and a proliferation-inducing ligand (April), in systemic lupus erythematosus (Sle): results of a phase 3 study [Abstract]. Arthritis Rheumatol (2022) 74(Suppl 9).</Citation></Reference><Reference><Citation>
Remegen Pharmaceuticals Inc . Telitacicept has been approved for a global multi-center phase iii clinical trial in sle in the eu and China (2022). Available at: http://www.Remegen.Com/Index.Php?V=Show&amp;Cid=83&amp;Id=914/ (Accessed 16 Oct 2022).</Citation></Reference><Reference><Citation>
Remegen Pharmaceuticals Inc . The fda has approved a phase iii clinical trial in iga nephropathy in the united states of telitacicept (2022). Available at: http://www.Remegen.Cn/Index.Php?V=Show&amp;Cid=39&amp;Id=939/ (Accessed 18 Nov 2022).</Citation></Reference><Reference><Citation>
Remegen Pharmaceuticals Inc . Telitacicept phase ii clinical data on iga nephropathy presented at the annual meeting of the American society of nephrology (2021). Available at: http://www.Remegen.Com/Index.Php?V=Show&amp;Cid=115&amp;Id=526/ (Accessed 18 Nov 2022).</Citation></Reference><Reference><Citation>
Remegen Pharmaceuticals Inc . Indication for telitacicept (2022). Available at: http://www.Remegen.Com/Index.Php?V=Show&amp;Cid=93&amp;Id=147/ (Accessed 31 Oct 2022).</Citation></Reference><Reference><Citation>Xu D, Zhang S, Huang C, Huang C, Qin L, Li X, et al. . Efficacy and safety of telitacicept in primary sj&#xf6;gren&#x2019;s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial [Abstract]. Arthritis Rheumatol (2022) 74(Suppl 9).</Citation></Reference><Reference><Citation>Remegen Pharmaceuticals Inc . Data from a phase ii study on the treatment of generalized myasthenia gravis with telitacicept (2022) (Accessed 31 Oct 2022).</Citation></Reference><Reference><Citation>Ding J, Cai Y, Deng Y, Jiang X, Gao M, Lin Y, et al. . Telitacicept following plasma exchange in the treatment of subjects with recurrent nmosd: study protocol for a single-center, single-arm, open-label study. Front Neurol (2021) 12:596791. doi:&#xa0;10.3389/fneur.2021.596791</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.596791</ArticleId><ArticleId IdType="pmc">PMC8044936</ArticleId><ArticleId IdType="pubmed">33868140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>